<abstract xmlns="http://www.w3.org/1999/xhtml"><p>A hypothesis testing, case-control study evaluated automated medical records for exposure to organic-Hg from Thimerosal-containing hepatitis B vaccines (TM-HepB) administered at specific intervals in the first six-months-of-life among cases diagnosed with a tic disorder (TD) or cerebral degeneration (CD) (an outcome not biologically plausibly linked to TM exposure) in comparison to controls; both cases and controls were continuously enrolled from birth (born from 1991–2000) within the Vaccine Safety Datalink (VSD) database. TD cases were significantly more likely than controls to have received increased organic-Hg from TM-HepB administered within the first month-of-life (odds ratio (OR)=1.59, <italic>p</italic>&lt;0.00001), first two-months-of-life (OR=1.59, <italic>p</italic>&lt;0.00001), and first six-months-of-life (OR=2.97, <italic>p</italic>&lt;0.00001). Male TD cases were significantly more likely than male controls to have received increased organic-Hg from TM-HepB administered within the first month-of-life (OR =1.65, <italic>p</italic>&lt;0.0001), first two-months-of-life (OR=1.64, <italic>p</italic>&lt;0.0001), and first six months-of-life (OR=2.47, <italic>p</italic>&lt;0.05), where as female TD were significantly more likely than female controls to have received increased organic-Hg from TM-HepB administered within the first six-months-of-life (OR=4.97, <italic>p</italic>&lt;0.05). By contrast, CD cases were no more likely than controls to have received increased organic-Hg exposure from TM-HepB administered at any period studied within the first six-months-of-life. Although routine childhood vaccination is considered an important public health tool to combat infectious diseases, the present study associates increasing organic-Hg exposure from TM-HepB and the subsequent risk of a TD diagnosis.</p></abstract>

A hypothesis testing, case-control study evaluated automated medical records for exposure to organic-Hg from Thimerosal-containing hepatitis B vaccines (TM-HepB) administered at specific intervals in the first six-months-of-life among cases diagnosed with a tic disorder (TD) or cerebral degeneration (CD) (an outcome not biologically plausibly linked to TM exposure) in comparison to controls; both cases and controls were continuously enrolled from birth (born from 1991–2000) within the Vaccine Safety Datalink (VSD) database. TD cases were significantly more likely than controls to have received increased organic-Hg from TM-HepB administered within the first month-of-life (odds ratio (OR)=1.59, p<0.00001), first two-months-of-life (OR=1.59, p<0.00001), and first six-months-of-life (OR=2.97, p<0.00001). Male TD cases were significantly more likely than male controls to have received increased organic-Hg from TM-HepB administered within the first month-of-life (OR =1.65, p<0.0001), first two-months-of-life (OR=1.64, p<0.0001), and first six months-of-life (OR=2.47, p<0.05), where as female TD were significantly more likely than female controls to have received increased organic-Hg from TM-HepB administered within the first six-months-of-life (OR=4.97, p<0.05). By contrast, CD cases were no more likely than controls to have received increased organic-Hg exposure from TM-HepB administered at any period studied within the first six-months-of-life. Although routine childhood vaccination is considered an important public health tool to combat infectious diseases, the present study associates increasing organic-Hg exposure from TM-HepB and the subsequent risk of a TD diagnosis.

Thimerosal exposure and increased risk for diagnosed tic disorder in the United States: a case-control study

Institute of Chronic Illnesses, Inc., 14 Redgate Ct, Silver Spring, MD, USA

Associate Professor of Biology, Simpson University, Redding, CA, USA

International Academy of Oral Medicine and Toxicology, ChampionsGate, FL, USA

Interdisciplinary Toxicology

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

A hypothesis testing, case-control study evaluated automated medical records for exposure to organic-Hg from Thimerosal-containing hepatitis B vaccines...

Thimerosal exposure and increased risk for diagnosed tic disorder in the United States: a case-control study

Publié en ligne: 07 mars 2016

Pages: 68 - 76

Reçu: 12 févr. 2015

Accepté: 23 avr. 2015

DOI: https://doi.org/10.1515/intox-2015-0011

Mots clés
ethylmercury, merthiolate, thiomersal, tic, tourette, vaccine

© 2015 Interdisciplinary Toxicology

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Thimerosal exposure and increased risk for diagnosed tic disorder in the United States: a case-control study

Publié en ligne: 07 mars 2016

Pages: 68 - 76

Reçu: 12 févr. 2015

Accepté: 23 avr. 2015

DOI: https://doi.org/10.1515/intox-2015-0011

Mots clésethylmercury, merthiolate, thiomersal, tic, tourette, vaccine

© 2015 Interdisciplinary Toxicology

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Mots clés
ethylmercury, merthiolate, thiomersal, tic, tourette, vaccine